Lupin names Dr Ranjana Pathak as Chief Quality Officer
Mumbai: Global pharma major Lupin Limited today announced the appointment of Dr Ranjana Pathak as Chief Quality Officer, succeeding Johnny Mikell who will be retiring from the services of the company. With over three decades of industry experience, Dr Pathak brings a wealth of expertise and leadership and will oversee all aspects of quality and regulatory compliance for Lupin’s global operations.
Dr Pathak’s career includes serving as the Global Head for Quality and Pharmacovigilance at Dr. Reddy’s. Prior to this, Dr Pathak served as the President & Global Head of Quality, Medical Affairs and Pharmacovigilance at Cipla and has also held Global Quality and Compliance leadership positions at Watson/Actavis and Endo Pharmaceuticals in the U.S. Dr. Pathak has strong experience across generic and brand medicines across dosage platforms including injectables, inhalation products and biologics.
“We extend our gratitude to Johnny for his valuable contribution to Lupin over the past five years,” said Vinita Gupta, CEO and Nilesh Gupta, MD, Lupin. “We are delighted to welcome Ranjana to our executive leadership team. Her extensive global experience and proven track record in building and sustaining a strong culture of quality and compliance align with Lupin’s commitment to be best-in-class in delivering quality products to the communities we serve.”
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 7.9% of its revenue in research and development in FY23.
Lupin has 15 manufacturing sites, 7 research centers.
Read also: Lupin bags USFDA nod for Eslicarbazepine Acetate Tablets for partial-onset seizures
